Mepolizumab Reduced Annual Systemic Corticosteroid Exposure in COPD Patients

Mepolizumab reduced annual systemic corticosteroid exposure compared with placebo in patients with COPD and type 2 inflammation.

The reduction in annual exposure was observed at both blood eosinophil thresholds evaluated.

The analysis included 2,089 patients across the METREX, METREO, and MATINEE trials, who were at least 40 years old, had COPD diagnosed at least one year earlier, and had a history of exacerbations while receiving inhaled triple therapy, and had no current asthma diagnosis.

Among the 1,713 participants with a BEC of at least 150 cells/µL, 1,144 had screening blood eosinophil counts of at least 300 cells/µL.

Photo: isacnet.org

In the 1,144 participants with a BEC of at least 300 cells/μL, 631 (55%) received corticosteroids for any reason.

At the 300 cells/µL threshold, exposure averaged 354.28 mg with mepolizumab and 551.52 mg with placebo.

Researchers combined data from METREX, METREO, and MATINEE trials which were all randomized and controlled against placebo according to Source 1 and Source 3.

Participants were randomized to receive 100 mg of subcutaneous mepolizumab or placebo every four weeks for up to 104 weeks, as reported by Source 4.

Among participants with a BEC of at least 150 cells/μL, 967 individuals, or 56%, received corticosteroids according to Source 2.

For patients with eosinophil counts ≥300 cells/μL, annual exposure was about 354 mg with mepolizumab versus 552 mg with placebo, a reduction of about 36%, stated Source 4.

Whether the reductions translated into fewer corticosteroid-related complications remains an open question.

The conference report quantified corticosteroid exposure and time on treatment Mepolizumab in COPD Lowers Annual Steroid Exposure Of the 2,089 patients enrolled across the trials.